NRG Energy Inc vs Novartis AG — how do they compare? NRG Energy Inc trades at $121.21 (market cap $24.83B), while Novartis AG trades at $154.71 (market cap $295.37B). The key difference: Novartis AG is far larger — about 11.9× NRG Energy Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NRG | NVS | |
|---|---|---|
Market Cap | $24.83B | $295.37B |
Sector | Utilities | Health |
52-Week High | $184.03 | $168.62 |
52-Week Low | $117.04 | $119.31 |
Enterprise Value | $48.79B | $336.69B |
Dividend Yield | 1.61% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $120.37, down 1.23% with a bearish technical signal. Recent Q2 2026 earnings missed estimates at $1.49 EPS versus $1.69 expected, though revenue grew 11% year-over-year. The company is advancing a 1.2 GW Texas data-center power project to capitalize on AI-driven electricity demand, supported by a 69% analyst buy rating and a $207.83 consensus price target. Cash flow from operations was $1.91B in 2025, but net income margin compressed to 2.56%.
Outlook is mixed: growth initiatives in data center power present upside, but execution risks and rising interest costs pressure margins. The stock offers a 1.6% dividend yield, yet high debt-to-asset ratio of 56.42% in 2025 warrants caution. Near-term support lies at $119, with resistance at $122.
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
Trailing returns across standard periods
Latest headlines on both assets
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →